LEADER 04518nam 2200661 450 001 9910208944903321 005 20231214154210.0 010 $a1-118-90618-7 010 $a1-119-20807-6 010 $a1-118-90619-5 035 $a(CKB)4330000000002711 035 $a(SSID)ssj0001555137 035 $a(PQKBManifestationID)16198238 035 $a(PQKBTitleCode)TC0001555137 035 $a(PQKBWorkID)14817738 035 $a(PQKB)22160280 035 $a(DLC) 2015016139 035 $a(Au-PeEL)EBL4436059 035 $a(CaPaEBR)ebr11169661 035 $a(CaONFJC)MIL839959 035 $a(OCoLC)898155834 035 $a(CaSebORM)9781118906132 035 $a(MiAaPQ)EBC4436059 035 $a(PPN)271975342 035 $a(EXLCZ)994330000000002711 100 $a20160330h20152015 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aEssential strategies for financial services compliance /$fAnnie Mills, Peter Haines 205 $aSecond edition. 210 1$aChichester, England :$cWiley,$d2015. 210 4$d©2015 215 $a1 online resource (527 pages) $cillustrations (some color), tables 300 $aIncludes index. 311 $aprint version 9781118906132 320 $aIncludes bibliographical references and index. 327 $aThe UK regulatory enviroment -- The compliance function -- The compliance contract -- Mapping your compliance universe -- Mapping your corporate universe -- Regulators and other industry bodies -- The legislative environment and rules mapping -- Financial products, services, and documentation -- Compliance outside the compliance department -- Key compliance department activities -- Comply or die : when things go wrong. 330 $a"A fully updated edition of the definitive guide to financial regulation In recent years, not only has the compliance field become firmly established, but it has seen staggering growth, thanks to never-ending changes in the regulatory environment. As regulation increases still further, the demand for clear guidance on navigating daily compliance issues is greater than ever. Now in its second edition, the highly successful Essential Strategies for Financial Services Compliance has been updated with the latest compliance strategies and regulatory information, making it indispensable for compliance officers, legal firms, and anyone else working with the financial services compliance function. Non-compliance represents a significant material risk for any financial services firm that fails to understand and appropriately apply regulatory standards. This Second Edition of Essential Strategies for Financial Services Compliance makes it easy to digest complex information on the regulatory framework. But this book is far from solely theoretical. A balanced approach means that both the concepts and their application are within reach. Annie Mills and Peter Haines deliver solid advice that can be applied on a day-to-day basis to manage any compliance issues that may arise. Read this book to: Understand the conceptual basis of compliance and the current regulatory environment applicable to the financial services industry Quickly and thoroughly learn the accepted best practices for everyday compliance Get up to date information on the current financial regulatory environment with this new edition Reference detailed advice as issues arise in day-to-day operations This update to the popular first edition of Essential Strategies for Financial Services Compliance will help eliminate non-compliance risk and ensure that your firm is entirely current on its ability to navigate the maze of financial services regulation"--$cProvided by publisher. 606 $aFinancial services industry$xLaw and legislation$zGreat Britain 606 $aCorporate governance$xLaw and legislation$zGreat Britain 606 $aEthics and compliance officers$zGreat Britain$vHandbooks, manuals, etc 615 0$aFinancial services industry$xLaw and legislation 615 0$aCorporate governance$xLaw and legislation 615 0$aEthics and compliance officers 676 $a346.41/082 686 $aBUS003000$2bisacsh 700 $aMills$b Annie$0848002 702 $aHaines$b Peter$f1959- 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910208944903321 996 $aEssential strategies for financial services compliance$91893839 997 $aUNINA LEADER 01133nam a2200265 4500 001 991003135719707536 005 20250430125950.0 008 950522n fr b 000 fre 035 $ab1428635x-39ule_inst 035 $aCICOGNARA-3838$9ExL 040 $aBibl. Interfacoltà T. Pellegrino$bita 041 0 $aFre. 100 1 $aRosa, Salvator$038079 245 10$aSalvator Rosa invenit 260 $aParis,$bDe Poitty$c[s.d.] 300 $a[58] :$btav. (incl. front.); $c19 cm. 500 $aRiproduzione in microfiche dell'originale conservato presso la Biblioteca Apostolica Vaticana 787 18$iLeopoldo Cicognara Program :$tBiblioteca Cicognara$h[microform] : literary sources in the history of art and kindred subjects 787 18$tCatalogo ragionato dei libri d'arte e d'antichità / Leopoldo Cicognara 907 $a.b1428635x$b01-04-22$c28-07-16 912 $a991003135719707536 945 $aLE002 SB Raccolta Cicognara, mcrf 2099$g0$lle002$pE0.00$rn$so $t11$u0$v0$w0$x0$y.i1575764x$z28-07-16 996 $aSalvator Rosa invenit$91390576 997 $aUNISALENTO 998 $ale002$b28-07-16$cm$dg $e-$ffre$gfr $h0$i1 LEADER 05361nam 22015613a 450 001 9910346684303321 005 20250203235429.0 010 $a9783039210619 010 $a3039210610 024 8 $a10.3390/books978-3-03921-061-9 035 $a(CKB)4920000000094826 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/54029 035 $a(ScCtBLL)9b5b364c-2670-4301-9845-c4b9a0365ea7 035 $a(OCoLC)1117844310 035 $a(oapen)doab54029 035 $a(EXLCZ)994920000000094826 100 $a20250203i20192019 uu 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$amTOR in Human Diseases$fOlivier Dormond 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2019 210 1$aBasel, Switzerland :$cMDPI,$d2019. 215 $a1 electronic resource (480 p.) 311 08$a9783039210602 311 08$a3039210602 330 $aThe mechanistic target of rapamycin (mTOR) is a major signaling intermediary that coordinates favorable environmental conditions with cell growth. Indeed, as part of two functionally distinct protein complexes, named mTORC1 and mTORC2, mTOR regulates a variety of cellular processes, including protein, lipid, and nucleotide synthesis, as well as autophagy. Over the last two decades, major molecular advances have been made in mTOR signaling and have revealed the complexity of the events implicated in mTOR function and regulation. In parallel, the role of mTOR in diverse pathological conditions has also been identified, including in cancer, hamartoma, neurological, and metabolic diseases. Through a series of articles, this book focuses on the role played by mTOR in cellular processes, metabolism in particular, and highlights a panel of human diseases for which mTOR inhibition provides or might provide benefits. It also addresses future studies needed to further characterize the role of mTOR in selected disorders, which will help design novel therapeutic approaches. It is therefore intended for everyone who has an interest in mTOR biology and its application in human pathologies. 606 $aMedicine$2bicssc 610 $aprimary cilia 610 $aneurodegeneration 610 $anutrient sensor 610 $aPI3K 610 $atranscriptomics 610 $aphosphorylation 610 $ametabolic reprogramming 610 $aautophagy 610 $aAlzheimer's disease 610 $arapalogs 610 $aliver 610 $aangiogenesis 610 $amTOR complex 610 $aMBSCs 610 $aadvanced biliary tract cancers 610 $aMedulloblastoma 610 $aepithelial to mesenchymal transition 610 $aAMPK 610 $ap70S6K 610 $alipid metabolism 610 $athyroid cancer 610 $asodium iodide symporter (NIS)/SLC5A5 610 $amale fertility 610 $aanesthesia 610 $aillumina 610 $amTOR inhibitor 610 $amiRNA 610 $aHutchinson-Gilford progeria syndrome (HGPS) 610 $aeIFs 610 $aEmery-Dreifuss muscular dystrophy (EDMD) 610 $aglucose 610 $aAKT 610 $aoral cavity squamous cell carcinoma (OSCC) 610 $aglucose and lipid metabolism 610 $acellular signaling 610 $aaging 610 $atumor microenvironment 610 $arapamycin 610 $aleukemia 610 $achloral hydrate 610 $arapalogues 610 $aschizophrenia 610 $aT-cell acute lymphoblastic leukemia 610 $asenescence 610 $alamin A/C 610 $aneurotoxicity 610 $aneurodevelopment 610 $ainhibitor 610 $amethamphetamine 610 $apulmonary fibrosis 610 $amTOR 610 $amTOR inhibitors 610 $acombination therapy 610 $aproteolysis 610 $afluid shear stress 610 $atumour cachexia 610 $abiomarkers 610 $asynapse 610 $agluconeogenesis 610 $amTOR signal pathway 610 $aSertoli cells 610 $aimmunosenescence 610 $amiRNome 610 $aprotein aggregation 610 $asenolytics 610 $ametabolism 610 $aNGS 610 $amTORC2 610 $amTORC1 610 $ametabolic diseases 610 $aIonTorrent 610 $aapoptosis 610 $adopamine receptor 610 $anocodazole 610 $amicroenvironment 610 $aeverolimus 610 $aacute myeloid leukemia 610 $aimmunotherapy 610 $aspermatogenesis 610 $abone remodeling 610 $asignalling 610 $atargeted therapy 610 $aageing 610 $atherapy 610 $aNVP-BEZ235 610 $afructose 610 $aphysical activity 610 $alaminopathies 610 $aMC3T3-E1 cells 610 $acell signaling 610 $amicroRNA 610 $acancer 610 $alipolysis 610 $amelatonin 610 $aParkinson's disease 615 7$aMedicine 700 $aDormond$b Olivier$01331033 801 0$bScCtBLL 801 1$bScCtBLL 906 $aBOOK 912 $a9910346684303321 996 $aMTOR in Human Diseases$93040048 997 $aUNINA